{"success":true,"data":{"pressRelease":{"id":"18401","rtpr_id":"nGNE8j60BY","ticker":"MOLN","exchange":"","all_tickers":["MOLN"],"title":"Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences","author":"Globe Newswire","published_at":"2026-05-04T05:00:00.218Z","article_body":"ZURICH-SCHLIEREN, Switzerland and Concord, Mass., May 04, 2026 (GLOBE\nNEWSWIRE) -- Molecular Partners\n(https://www.globenewswire.com/Tracker?data=kAdYzxV7NOkXDxY-3fvIZnFEruEywkFWhd5ihgX16VsoSX-Ir2Kw9aBcMaX51fuz20tqH0Os1kX9DT-qJDvrn9ukl0DFw4BlVLAtXckKDvY=)\nAG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a\nnovel class of custom-built protein drugs known as DARPin therapeutics, today\nannounced its attendance and presentations on its lead Radio-DARPin candidate\nMP0712 at upcoming scientific conferences.\n\nDetails of the events:\n\nNIH National Cancer Institute 2026 Small Cell Lung Cancer Consortium Meeting \nMay 6–7, Rockville, MD, USA \nTitle: Molecular characteristics of MP0712, a clinical stage ²¹²Pb-based\nRadio-DARPin candidate for targeted anti-DLL3 radiotherapy of small cell lung\ncancer (SCLC) \nSession: New Therapy Targets\nDate & Time: 7 May 2026; 10:30–10:45 am local time\n\n22(nd) Annual PEGS Boston\nMay 11–15, Boston, MA, USA\nTitle: Advancing Radio-DARPin therapeutics: from preclinical insights to\nclinical development\nSession: Novel Platforms and Preclinical-to-Clinical Strategies\nDate & Time: 13 May 2026; 2:40–3:10 pm local time\n\nAntibody & Engineering Therapeutics \nMay 27–29, Basel, Switzerland Title: Radio-DARPins for targeted alpha\ntherapy: first in human insights with MP0712 and opportunities for future\ncandidates\nTrack: ADCs & Bioconjugates – Advancing ADCs to the Clinic \nDate & Time: 29 May 2026; 4:45–5:15 pm local time\n\nAbout Molecular Partners AG \nMolecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech\ncompany pioneering a novel class of protein drugs known as DARPin\ntherapeutics, for medical challenges other treatment modalities cannot readily\naddress. Molecular Partners leverages the key properties of DARPins to design\nand develop differentiated therapeutics for cancer patients, including\ntargeted radiopharmaceuticals and next-generation immune cell engagers. The\nCompany has proprietary programs in various stages of pre-clinical and\nclinical development, as well as programs developed through partnerships with\nleading pharmaceutical companies and academic centers. Molecular Partners,\nfounded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA.\nFor more information, visit www.molecularpartners.com and find us on LinkedIn\nand Twitter / X @MolecularPrtnrs\n\nFor further details, please contact:\nSeth Lewis, EVP Corporate Finance\nConcord, Massachusetts, U.S.\nseth.lewis@molecularpartners.com\nTel: +1 781 420 2361\n\nLaura Jeanbart, PhD, Head of Portfolio Management & Communications \nZurich-Schlieren, Switzerland\nlaura.jeanbart@molecularpartners.com \nTel: +41 44 575 19 35\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements. Any statements\ncontained in this press release that do not describe historical facts may\nconstitute forward-looking statements as that term is defined in the Private\nSecurities Litigation Reform Act of 1995, as amended, including without\nlimitation: implied and express statements regarding the clinical development\nof Molecular Partners’ current or future product candidates; expectations\nregarding timing for reporting data from ongoing clinical trials or the\ninitiation of future clinical trials; the potential therapeutic and clinical\nbenefits of Molecular Partners’ product candidates and its RDT and\nSwitch-DARPin platforms; the selection and development of future programs;\nMolecular Partners’ collaboration with Orano Med including the benefits and\nresults that may be achieved through the collaboration; the expected benefits\nof the strategic review; and Molecular Partners’ expected business and\nfinancial outlook, including anticipated expenses and cash utilization for\n2026 and its expectation of its current cash runway. These statements may be\nidentified by words such as “aim”, “anticipate”, “expect”,\n“guidance”, “intend”, “outlook”, “plan”, “potential”,\n“will” and similar expressions, and are based on Molecular Partners’\ncurrent beliefs and expectations. These statements involve risks and\nuncertainties that could cause actual results to differ materially from those\nreflected in such statements. Some of the key factors that could cause actual\nresults to differ from Molecular Partners’ expectations include, but are not\nlimited to, those set forth in under the heading “Risk Factors” in\nMolecular Partners’ Annual Report on Form 20-F for the year ended December\n31, 2025 and other filings Molecular Partners makes with the SEC from time to\ntime. These documents are available on the Investors page of Molecular\nPartners’ website at www.molecularpartners.com. In addition, this press\nrelease contains information relating to interim data as of the relevant data\ncutoff date, results of which may differ from topline results that may be\nobtained in the future.\n\nAny forward-looking statements speak only as of the date of this press release\nand are based on information available to Molecular Partners as of the date of\nthis release, and Molecular Partners assumes no obligation to, and does not\nintend to, update any forward-looking statements, whether as a result of new\ninformation, future events or otherwise.","article_body_html":"","raw_payload":{"data":{"id":"nGNE8j60BY","title":"Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences","author":"Globe Newswire","ticker":"MOLN","created":"2026-05-04T05:00:00.218Z","tickers":["MOLN"],"exchange":"","article_body":"ZURICH-SCHLIEREN, Switzerland and Concord, Mass., May 04, 2026 (GLOBE\nNEWSWIRE) -- Molecular Partners\n(https://www.globenewswire.com/Tracker?data=kAdYzxV7NOkXDxY-3fvIZnFEruEywkFWhd5ihgX16VsoSX-Ir2Kw9aBcMaX51fuz20tqH0Os1kX9DT-qJDvrn9ukl0DFw4BlVLAtXckKDvY=)\nAG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a\nnovel class of custom-built protein drugs known as DARPin therapeutics, today\nannounced its attendance and presentations on its lead Radio-DARPin candidate\nMP0712 at upcoming scientific conferences.\n\nDetails of the events:\n\nNIH National Cancer Institute 2026 Small Cell Lung Cancer Consortium Meeting \nMay 6–7, Rockville, MD, USA \nTitle: Molecular characteristics of MP0712, a clinical stage ²¹²Pb-based\nRadio-DARPin candidate for targeted anti-DLL3 radiotherapy of small cell lung\ncancer (SCLC) \nSession: New Therapy Targets\nDate & Time: 7 May 2026; 10:30–10:45 am local time\n\n22(nd) Annual PEGS Boston\nMay 11–15, Boston, MA, USA\nTitle: Advancing Radio-DARPin therapeutics: from preclinical insights to\nclinical development\nSession: Novel Platforms and Preclinical-to-Clinical Strategies\nDate & Time: 13 May 2026; 2:40–3:10 pm local time\n\nAntibody & Engineering Therapeutics \nMay 27–29, Basel, Switzerland Title: Radio-DARPins for targeted alpha\ntherapy: first in human insights with MP0712 and opportunities for future\ncandidates\nTrack: ADCs & Bioconjugates – Advancing ADCs to the Clinic \nDate & Time: 29 May 2026; 4:45–5:15 pm local time\n\nAbout Molecular Partners AG \nMolecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech\ncompany pioneering a novel class of protein drugs known as DARPin\ntherapeutics, for medical challenges other treatment modalities cannot readily\naddress. Molecular Partners leverages the key properties of DARPins to design\nand develop differentiated therapeutics for cancer patients, including\ntargeted radiopharmaceuticals and next-generation immune cell engagers. The\nCompany has proprietary programs in various stages of pre-clinical and\nclinical development, as well as programs developed through partnerships with\nleading pharmaceutical companies and academic centers. Molecular Partners,\nfounded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA.\nFor more information, visit www.molecularpartners.com and find us on LinkedIn\nand Twitter / X @MolecularPrtnrs\n\nFor further details, please contact:\nSeth Lewis, EVP Corporate Finance\nConcord, Massachusetts, U.S.\nseth.lewis@molecularpartners.com\nTel: +1 781 420 2361\n\nLaura Jeanbart, PhD, Head of Portfolio Management & Communications \nZurich-Schlieren, Switzerland\nlaura.jeanbart@molecularpartners.com \nTel: +41 44 575 19 35\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements. Any statements\ncontained in this press release that do not describe historical facts may\nconstitute forward-looking statements as that term is defined in the Private\nSecurities Litigation Reform Act of 1995, as amended, including without\nlimitation: implied and express statements regarding the clinical development\nof Molecular Partners’ current or future product candidates; expectations\nregarding timing for reporting data from ongoing clinical trials or the\ninitiation of future clinical trials; the potential therapeutic and clinical\nbenefits of Molecular Partners’ product candidates and its RDT and\nSwitch-DARPin platforms; the selection and development of future programs;\nMolecular Partners’ collaboration with Orano Med including the benefits and\nresults that may be achieved through the collaboration; the expected benefits\nof the strategic review; and Molecular Partners’ expected business and\nfinancial outlook, including anticipated expenses and cash utilization for\n2026 and its expectation of its current cash runway. These statements may be\nidentified by words such as “aim”, “anticipate”, “expect”,\n“guidance”, “intend”, “outlook”, “plan”, “potential”,\n“will” and similar expressions, and are based on Molecular Partners’\ncurrent beliefs and expectations. These statements involve risks and\nuncertainties that could cause actual results to differ materially from those\nreflected in such statements. Some of the key factors that could cause actual\nresults to differ from Molecular Partners’ expectations include, but are not\nlimited to, those set forth in under the heading “Risk Factors” in\nMolecular Partners’ Annual Report on Form 20-F for the year ended December\n31, 2025 and other filings Molecular Partners makes with the SEC from time to\ntime. These documents are available on the Investors page of Molecular\nPartners’ website at www.molecularpartners.com. In addition, this press\nrelease contains information relating to interim data as of the relevant data\ncutoff date, results of which may differ from topline results that may be\nobtained in the future.\n\nAny forward-looking statements speak only as of the date of this press release\nand are based on information available to Molecular Partners as of the date of\nthis release, and Molecular Partners assumes no obligation to, and does not\nintend to, update any forward-looking statements, whether as a result of new\ninformation, future events or otherwise."},"type":"article","timestamp":"2026-05-04T05:00:00.331116636Z","server_sent_at_ms":1777870800331},"received_at":"2026-05-04T05:00:00.390Z","source_url":"https://www.globenewswire.com/news-release/2026/02/02/3229944/0/en/molecular-partners-announces-presentation-of-first-imaging-and-dosimetry-data-of-dll3-targeting-radiotherapy-mp0712-in-patients-at-twc-2026.html"},"analysis":{"id":"13302","press_release_id":"18401","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Molecular Partners announced that it will deliver oral presentations on its lead Radio-DARPin candidate MP0712 at three upcoming scientific conferences in May.\n\nThe first presentation on May 7 at the NIH NCI Small Cell Lung Cancer Consortium Meeting will focus on the molecular characteristics of MP0712 for targeted anti-DLL3 radiotherapy.\n\nAdditional presentations at PEGS Boston and the Antibody & Engineering Therapeutics conference will discuss preclinical insights, clinical development, and first-in-human insights.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference attendance announcement."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Seth Lewis","role":"EVP Corporate Finance"},{"name":"Laura Jeanbart","role":"Head of Portfolio Management & Communications"}],"products":["MP0712","Radio-DARPin","DARPin therapeutics"],"companies":[{"name":"Molecular Partners AG","ticker":"MOLN"},{"name":"NIH National Cancer Institute","relationship":"conference host"},{"name":"Orano Med","relationship":"partner"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of conference participation and presentation schedules. No clinical data readout, financial results, or material business developments were disclosed in the release."},"tickerRelevance":{"others":[],"primary":"MOLN"},"globalImportance":12,"audienceRelevance":18,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small_cap","dataContent":"none","eventGravity":"operational_update"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Molecular Partners announced that it will deliver oral presentations on its lead Radio-DARPin candidate MP0712 at three upcoming scientific conferences in May.\n\nThe first presentation on May 7 at the NIH NCI Small Cell Lung Cancer Consortium Meeting will focus on the molecular characteristics of MP0712 for targeted anti-DLL3 radiotherapy.\n\nAdditional presentations at PEGS Boston and the Antibody & Engineering Therapeutics conference will discuss preclinical insights, clinical development, and first-in-human insights.","key_figures":{},"named_entities":{"people":[{"name":"Seth Lewis","role":"EVP Corporate Finance"},{"name":"Laura Jeanbart","role":"Head of Portfolio Management & Communications"}],"products":["MP0712","Radio-DARPin","DARPin therapeutics"],"companies":[{"name":"Molecular Partners AG","ticker":"MOLN"},{"name":"NIH National Cancer Institute","relationship":"conference host"},{"name":"Orano Med","relationship":"partner"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-04T05:01:35.201Z","global_importance":12,"audience_relevance":18,"importance_components":{"tickerTier":"small_cap","dataContent":"none","eventGravity":"operational_update"}},"durationMs":94174,"modelName":"glm-4.7"}}